Topic

Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

Agency panel backs the use of a common bivalent shot for all patients.

Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation?

In adjusting to the long-term aftershocks from the coronavirus pandemic, pharma companies will need to focus on change in three core areas.

The key industry areas that will experience downstream pressures in the wake of the coronavirus pandemic.